TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03980145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EO System (Reha Technology AG: Olten, Switzerland)
Description: Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
Study: NCT00921557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet taken once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet taken once weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate/vitamin D
Description: Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate/vitamin D
Description: Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate/vitamin D
Description: Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
Study: NCT03055299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMEX intervention
Description: Comprehensive Exercise
Study: NCT02883049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study: NCT02743936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal cannula
Description: Placement of nasal cannula under non-invasive positive pressure ventilation mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation
Description: Non-invasive positive pressure ventilation
Study: NCT02883049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study: NCT02743936

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilation
Description: Non-invasive positive pressure ventilation
Study: NCT04675671

Intervention type: OTHER
Intervention: Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]
Description: The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
Study: NCT02883049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study: NCT02956876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy for colorectal cancer
Description: standard chemotherapy for colorectal cancer

Intervention type: DRUG
Group type: OTHER
Intervention: standard chemotherapy for colorectal cancer
Description: standard chemotherapy for colorectal cancer
Study: NCT02883049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study: NCT02956876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse practitioner consultation
Description: Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer

Intervention type: OTHER
Group type: OTHER
Intervention: Medical practitioner consultation
Description: Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
Study: NCT02883049

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01878253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sidus Stem-Free Total Shoulder Arthroplasty System
Study: NCT02883049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02209688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR 1150 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR 1150 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00672347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 1 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 20 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus clonidine and morphine
Description: bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
Study: NCT02959255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: dosage difference
Study: NCT03305341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
Description: * Intradermic Injection, ID~* COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection
Study: NCT03637205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECLS insertion
Description: After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revascularisation and optimal medical treatment
Description: After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Revascularisation and optimal medical treatment
Description: After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
Study: NCT03896646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT HIDA scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatobiliary Iminodiacetic Acid Scan
Description: Undergo SPECT/CT HIDA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT HIDA scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Undergo radioembolization with yttrium Y 90 glass microspheres

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo yttrium-90 microsphere radioembolization
Study: NCT03995173

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Study: NCT04947774

Intervention type: RADIATION
Intervention: Prophylactic Cranial Irradiation
Description: The extensive-stage SCLC patients will receive prophylactic cranial irradiation ±immunotherapy after standard first-line chemotherapy combined with immunotherapy, until disease progression or death
Study: NCT04120077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Description: Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Description: Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Description: Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
Study: NCT00016432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg for 5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02075216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myoblast Transplantation
Description: For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
Study: NCT03551509

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ArthroFLEX ECM scaffold graft
Description: In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Crossover
Description: Patients randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
Study: NCT04755439

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DHCA
Description: DHCA THE USE OF SEREBRAL PROTECTİON TECHNİQUE
Study: NCT04373239

Intervention type: PROCEDURE
Intervention: Assisted Reproductive Technology
Description: Assisted reproductive technology includes IVF and IVF+ICSI.
Study: NCT02119611

Intervention type: DEVICE
Group type: OTHER
Intervention: Deep Brain Stimulation management
Description: The DBS surgery will be performed according to standard of care in the centers of referral. If performed at the NIH, this will be done under protocol 11-N-0211 or other protocols permitting DBS surgery depending on future availability.
Study: NCT02075216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neonatal Cystourethroscope Injection
Description: 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
Study: NCT01155440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1% Lidocaine 1mg/kg/hr IV drip x 48hr
Study: NCT02975934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate or Enzalutamide or Docetaxel
Description: Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
Study: NCT02724631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TubeClear® intervention
Description: The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
Study: NCT03644186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy plus HER2 Blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Chemotherapy plus HER2 Blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Chemotherapy plus HER2 Blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study: NCT01155440

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block
Description: 0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
Study: NCT02818946

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: Detection of cancer by MRI for pathologic nipple discharge
Study: NCT01193374

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician enhanced screening and counseling prompts
Description: PDA based health risk screening for well child issues and obesity risks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician enhanced screening and counseling prompts
Description: PDA based health risk screening for well child issues and obesity risks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education and motivational materials
Description: Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: basic educational brochure
Description: Booklet by ADA sent x 1.
Study: NCT00955409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001(3µg) + QS21
Description: Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
Study: NCT03644186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
Study: NCT00776984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 5mcg/day
Description: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
Study: NCT04610671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG0070
Description: CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with 5% DDM and normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Two neoadjuvant doses of nivolumab 480 mg Q4W (every 4 weeks) for 2 doses (week 2 and 6)